Effectiveness of Oil Pulling Using Oils in Comparison With Mouthwash for Gingivitis

Gingivitis represents a reversible bacterial-induced inflammatory condition affecting the gingival tissues surrounding the teeth. It is recognized as the earliest clinical stage of periodontal disease, which, if left unmanaged, can progress to irreversible periodontitis with alveolar bone loss and tooth loss. Global epidemiological figures from the World Health Organization (WHO, 2022) indicate that oral diseases affect approximately 3.5 billion individuals worldwide, with three-quarters of affected populations residing in low- and middle-income countries. Periodontal diseases alone affect nearly 50% of the global adult population, representing a substantial public health burden. In Pakistan, epidemiological data demonstrate a high prevalence of plaque-induced gingivitis ranging between 30% and 55% among dental outpatient clinic visitors in major urban hubs like Karachi, driven by limited socioeconomic resources, suboptimal personal oral hygiene practices, and restricted access to preventive dental care.

Pathophysiologically, dental plaque is an organized microbial biofilm that initiates on tooth surfaces following the rapid adsorption of salivary proteins and glycoproteins, forming an acquired pellicle within minutes. Soft gelatinous bacterial deposits accumulate preferentially along the gingival margin where mechanical friction from normal mastication is minimal. In the classic experimental gingivitis model established by Harold Loe in 1965, the complete cessation of mechanical tooth cleaning consistently resulted in generalized gingival inflammation within 7 to 21 days, characterized by capillary dilation, erythema, edema, and bleeding on gentle probing. Upon resuming proper oral hygiene measures, gingival health was restored within 7 to 10 days, establishing dental plaque as the primary and essential etiological driver of gingivitis.

When dental biofilm is allowed to mature without intervention, facultative and anaerobic pathogenic bacteria proliferate. Dysbiotic shift leads to the dominance of Gram-negative anaerobes, specifically complex species including Porphyromonas gingivalis, Treponema denticola, Tannerella forsythia (red complex), and Fusobacterium nucleatum, Prevotella intermedia (orange complex). Bacterial metabolic byproducts and endotoxins trigger host immune responses, causing localized vascular leakage, destruction of connective tissue collagen, and gingival exudation.

2. Comparative Pharmacological Rationale \& Therapeutic Mechanisms Standard clinical management relies on mechanical plaque removal (scaling and toothbrushing) combined with adjunctive chemical anti-plaque agents. Chlorhexidine digluconate (0.2%) is widely accepted as the clinical gold standard chemical mouthwash due to its strong cationic bisbiguanide broad-spectrum antimicrobial activity and high oral substantivity. However, prolonged or continuous daily use of chlorhexidine is strictly limited by well-documented adverse secondary effects, including heavy extrinsic tooth staining, altered taste sensation (dysgeusia), oral mucosal desquamation, subjective burning sensations, and accelerated supragingival calculus formation. These side effects severely restrict patient compliance for long-term home use.

Oil pulling (oil swishing) is a traditional oral hygiene practice originating from Ayurvedic medicine that involves swishing approximately 10 to 15 mL of edible vegetable oil through the interdental spaces and oral cavity for an extended duration. Mechanistically, oil pulling operates through several complementary pathways:

Saponification \& Alkali Hydrolysis: Salivary enzymes and mild alkaline oral pH interact with lipid triglycerides during continuous motion, inducing fat hydrolysis and soap-like emulsification that cleanses plaque deposits and detachment of bacterial bio-films.

Viscous Physical Barrier \& Hydrophobic Disruption: The high viscosity of natural lipid oils forms a thin hydrophobic protective film over enamel surfaces, inhibiting bacterial adhesion, pellicle cross-linking, and subsequent microbial colonization.

Sesame Oil Bioactive Lignans: Sesame oil contains bioactive sesamin, sesamolin, and sesaminol, which possess potent free-radical scavenging, antioxidant, and anti-inflammatory properties that reduce mucosal vascular permeability and oxidative tissue degradation.

Coconut Oil Lauric Acid Antimicrobial Action: Virgin coconut oil is composed of approximately 50% lauric acid (a medium-chain fatty acid). Lauric acid reacts with salivary bicarbonates to form sodium laurate, exhibiting selective antibacterial action against Gram-positive and Gram-negative oral pathogens without disturbing normal physiological flora.

Despite the widespread traditional utilization of oil pulling, a major scientific gap persists due to the scarcity of rigorous, single-blind, three-arm parallel randomized controlled clinical trials directly comparing natural edible oils (Virgin Coconut Oil vs. Sesame Oil) against 0.2% Chlorhexidine across standardized clinical indices (Plaque Index, Gingival Index, Tongue Coating Index, Stain Index, Salivary pH, and Quality of Life). This trial provides region-specific, evidence-based data for low-cost, accessible personal oral health maintenance in Pakistan.

3. Detailed Study Design, Allocation \& Blinding Procedures This research is structured as a single-blind, parallel three-arm randomized controlled clinical trial conducted at the Department of Periodontology Dental Outpatient Department (OPD), Bahria University Health Sciences Campus Karachi (BUHSCK), over an 8-week (56-day) active intervention period. The institutional ethical approval was formally granted by the Institutional Review Board (BUHS-IRB # 268/26).

To eliminate clinical evaluation bias, a single-blind outcome assessor model is implemented. Due to the distinct physical taste, aroma, and viscosity of natural oils versus chemical mouthwash, blinding of trial participants is unfeasible. However, the examining dentist who records all clinical indices at baseline (T1), week 4 (T2), and week 8 (T3) remains strictly blinded to participant allocation throughout the trial. An independent laboratory assistant who is not involved in participant recruitment or outcome evaluation performs the liquid dispensing in identical sequentially numbered, dark-amber opaque bottles. Randomization allocation codes are stored in sealed opaque envelopes under the secure custody of the principal supervisor and will remain unblinded only after complete statistical analysis.

To ensure clinical measurement reliability, the blinded examining dentist undergoes pre-trial intra-observer calibration supervised by a senior periodontologist. Calibration requires repeated scoring of plaque and gingival indices on non-study gingivitis patients to establish an intra-examiner Kappa reliability coefficient >= 0.85.

4. Intervention Administration Protocol \& Compliance Monitoring Prior to initiating the study products at Day 0 (T1), all 45 enrolled participants undergo full-mouth professional dental prophylaxis (scaling) to establish a standardized clean baseline oral hygiene state. All participants receive identical oral hygiene kits containing standardized toothbrushes, toothpaste, and detailed verbal and written instructions to perform the Modified Bass toothbrushing technique three times daily throughout the 56-day study period.

Participants in the oil pulling groups (CO and SO) are instructed to perform swishing immediately upon waking prior to breakfast or oral hygiene. Using calibrated measuring cups, 10 mL of assigned oil is swished between teeth and oral cavity for 7 minutes until thin and milky-white, then discarded into paper towels. Participants then gently rinse with warm water before brushing. Chlorhexidine participants rinse 10 mL for 1 minute at night after brushing. Each participant receives an initial 280 mL allotment (28-day supply) at Baseline (T1) and a second 280 mL allotment at Week 4 (T2). Adherence is tracked via daily paper tick logs and volumetric measurement of returned bottles at T2 and T3 visits.

5. Detailed Clinical Measurement Protocols \& Formulas

Clinical assessments are performed under standardized dental chair lighting at Baseline (T1), Day 28 / Week 4 (T2), and Day 56 / Week 8 (T3) using calibrated dental mirrors and WHO periodontal probes. Excluded from index evaluation are third molars, heavily carious teeth, and dental implants. Detailed scoring protocols include:

Silness \& Loe Plaque Index (PI): Evaluates plaque thickness along four gingival sites per tooth (facial, lingual, mesial, distal). Criteria: Score 0 = No plaque; Score 1 = Thin film detected only by probe; Score 2 = Moderate visible deposits; Score 3 = Heavy plaque accumulation filling pockets/interdental spaces. Calculation: Mean PI per tooth = Sum of 4 site scores / 4. Patient Mean PI = Sum of tooth means / Number of teeth evaluated. Score ranges: 0 (Very Good), 0.1-0.9 (Good), 1.0-1.9 (Satisfactory), 2.0-3.0 (Unsatisfactory).

Loe \& Silness Gingival Index (GILS): Assesses gingival inflammation severity across four sites per tooth (facial, lingual, mesial, distal). Criteria: Score 0 = Normal gingiva, no inflammation/bleeding; Score 1 = Mild inflammation, slight color change, no bleeding; Score 2 = Moderate inflammation, redness, edema, bleeding on probing; Score 3 = Severe inflammation, spontaneous bleeding, ulceration. Calculation: Mean GILS = Sum of all site scores / (4 x number of examined teeth).

Winkel Tongue Coating Index (WTCI): Evaluates tongue biofilm accumulation across six designated anatomical dorsum zones (3 posterior, 3 anterior). Criteria per zone: Score 0 = No coating; Score 1 = Light thin coating (pink tongue visible); Score 2 = Heavy thick coating (no pink color visible). Calculation: WTCI Total Score = Sum of 6 zone scores (Range: 0 to 12). Interpretation: 0 (Healthy), 1-3 (Mild), 4-6 (Moderate), 7-9 (Heavy), 10-12 (Severe).

Modified Lobene Stain Index (MLSI): Measures extrinsic enamel discoloration intensity (I) and area coverage (A) on facial and lingual surfaces of anterior teeth (teeth 12, 11, 21, 22, 32, 31, 41, 42). Intensity (I): 0 = No stain, 1 = Light yellow/brown, 2 = Moderate brown/orange, 3 = Heavy dark brown/black. Area (A): 0 = No stain, 1 = \<1/3 covered, 2 = 1/3-2/3 covered, 3 = >2/3 covered. Formula: Per-tooth Stain Score = Intensity (I) x Area (A) [Range 0-9]. Patient Mean MLSI = Sum of per-tooth product scores / Number of teeth examined.

Salivary pH Determination: Unstimulated resting whole saliva is collected in sterile containers and evaluated immediately using calibrated pH paper indicator strips matched against a standardized colorimetric reference chart.

Patient-Reported Outcomes (OHIP-14 \& PROs): Gingival symptoms (burning, dryness, breath improvement, intention of use) rated on a 5-point Likert scale (0=Never to 5=Always). Dental sensitivity, mucosal tissue pain, and product satisfaction assessed via Visual Analog Scale (VAS 0-10). Oral Health-Related Quality of Life evaluated using the validated 14-item Oral Health Impact Profile (OHIP-14) covering 7 domains (functional limitation, physical pain, psychological discomfort, physical disability, psychological disability, social disability, handicap). Likert scoring (0=Never to 4=Very Often); Total Score Range 0-56 (higher score indicates greater negative impact).

6. Sample Size Power Calculation \& Statistical Analysis Plan (SAP) Sample size calculation was performed a priori using G*Power software (version 3.1.9.7) for an F-test ANOVA repeated measures design (within-between interaction) across three parallel study arms and three measurement timepoints (Baseline, Week 4, Week 8). Assuming a moderate Cohen's f effect size of 0.25, a statistical significance power of 80% (1 - beta = 0.80), an alpha error probability of 0.05 (alpha = 0.05), and a correlation among repeated measures of 0.5, the required minimum sample size was calculated as 36 participants (12 per group). To account for an anticipated 20% patient dropout rate over 8 weeks, the target sample size was increased to 45 participants (15 participants per arm).

Statistical analysis will be executed using IBM SPSS Statistics version 23. Continuous parametric clinical data (Plaque Index, Gingival Index, WTCI, MLSI, Salivary pH, OHIP-14 scores) will be presented as Mean +/- Standard Deviation (SD), while categorical variables will be expressed as frequency counts and percentages. Data normality distribution will be confirmed via Shapiro-Wilk testing prior to parametric analysis.

Primary and secondary outcome comparisons across time (baseline, 4 weeks, 8 weeks) and study groups (CO, SO, CHX) will be evaluated using mixed-design repeated measures ANOVA. Mauchly's test of sphericity will verify variance-covariance equality assumptions; in cases where sphericity is violated, Greenhouse-Geisser epsilon corrections will be applied. Post-hoc pairwise comparisons between arms will be performed using Bonferroni correction adjustment for multiple testing. A two-tailed p-value \<= 0.05 will be defined as statistically significant for all tests.

7. Patient Safety, Ethical Compliance \& Data Governance The trial protocol adheres strictly to the ethical principles of the Declaration of Helsinki and local regulatory requirements. All participants provide voluntary signed dual-language (English/Urdu) informed consent after receiving comprehensive verbal and written descriptions of trial procedures. Participant confidentiality is maintained by replacing personal identifiers with unique alphanumeric coding numbers.

Safety monitoring is conducted at Week 4 and Week 8 visits. Participants are provided dedicated institutional contact numbers to immediately report adverse reactions, such as oral mucosal irritation, burning sensations, or allergic responses. In the event of documented adverse events, assigned intervention will be discontinued immediately, necessary dental or medical treatment will be provided at BUHSCK at no cost, and the event will be reported to the IRB and included in the final safety analysis.